MULTIPLE MYELOMA REFRACTORY
Clinical trials for MULTIPLE MYELOMA REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new MULTIPLE MYELOMA REFRACTORY trials appear
Sign up with your email to follow new studies for MULTIPLE MYELOMA REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a simple shot replace hospital stays for myeloma patients?
Disease control Not yet recruitingThis study tests whether the drug elranatamab can be given safely in an outpatient clinic instead of the hospital for people with multiple myeloma that has come back or stopped responding to treatment. About 46 adults will receive the drug along with a single preventive dose of a…
Matched conditions: MULTIPLE MYELOMA REFRACTORY
Phase: PHASE2 • Sponsor: SCRI Development Innovations, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New 'Off-the-Shelf' CAR-T therapy takes on Hard-to-Treat myeloma
Disease control Not yet recruitingThis early-phase trial is testing DQ1001, a ready-made CAR-T cell therapy that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is designed for patients whose multiple myeloma has returned or stopped responding to at least three prior treatments. The study will enroll …
Matched conditions: MULTIPLE MYELOMA REFRACTORY
Phase: PHASE1 • Sponsor: Zhongshan Hospital (Xiamen), Fudan University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New CAR T-Cell therapy targets Hard-to-Treat myeloma
Disease control Not yet recruitingThis early-stage trial tests the safety of a new CAR T-cell therapy, UF-KURE-BCMA, in 12 adults with multiple myeloma that has returned or not responded to other treatments. The therapy uses specially engineered immune cells to target and attack cancer cells. The main goal is to …
Matched conditions: MULTIPLE MYELOMA REFRACTORY
Phase: PHASE1 • Sponsor: Kure Cells, INC • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New CAR t therapy aims to tackle tough multiple myeloma
Disease control Not yet recruitingThis early-stage trial is testing a new treatment called SENL103 for people with multiple myeloma that has returned or not responded to standard treatments. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The study will enroll 24 parti…
Matched conditions: MULTIPLE MYELOMA REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Why do blood cancer patients skip home care? new study aims to find out.
Knowledge-focused Not yet recruitingThis study looks at why some people with blood cancers like multiple myeloma or lymphoma choose not to receive treatment at home, or are not eligible for it. Researchers will interview patients, their caregivers, and healthcare staff, and review medical records and questionnaires…
Matched conditions: MULTIPLE MYELOMA REFRACTORY
Sponsor: Odense University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC